Bauer KA et al. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in Phase II and III
colorectal cancer clinical trials. Clin Colorectal Cancer 2008;7(5):309-14. Abstract

Beldner M et al. Localized palmar-plantar epidermal hyperplasia: A previously undefined dermatologic toxicity to sorafenib. Oncologist 2007;12(10):1178-82. Abstract

Faivre S et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35. Abstract

Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: Retrospective analysis of patients treated at MD Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16(8):1289-96. Abstract

Hutson TE. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: A Phase III overview. Expert Rev Anticancer Ther 2007;7(9):1193-202. Abstract

Kollmannsberger C et al. Sunitinib therapy for metastatic renal cell carcinoma: Recommendations for management of side effects. Can Urol Assoc J 2007;1(2 Suppl):41-54. Abstract

Lountzis NI, Maroon MS. Sorafenib-induced palmoplantar hyperkeratosis. J Drugs Dermatol 2008;7(6):588-9. Abstract

Racca P et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer
2008;7(1):48-54. Abstract

Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007;6(2):175-82. Abstract

Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Huntingt) 2004;18(9):1161-8, 1173. Abstract

Scope A et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25(34):5390-6. Abstract

Strumberg D et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006;42(4):548-56. Abstract

Susnjar S et al. Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. Support Care Cancer 2008;[Epub ahead of print]. Abstract

Yang CH et al. Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158(3):592-6. Abstract